For generations, the gap between animal trials and human outcomes has quietly undermined medicine's promise — most drugs that pass in mice fail in people. Now Britain is investing £20 million in a Cambridge hub to grow miniature human organs from patient cells, asking a more honest question: does this drug work in human tissue? It is a shift not merely in technique but in the philosophy of how we understand disease and who we ask to bear the burden of discovery.